Stefanie Flohr

This inventor holds 26 USPTO granted patents and 2 published patent applications and 6 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Sanofi-A Ventis Deutschland Gmbh, Novartis Ag, Aventis Pharma Deutschland, Gmbh. Active years: 2002-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefanie Flohr. Retrieved from https://idiyas.com/inventor/stefanie-flohr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 2)

% Patents Active = 34.6

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 92(Granted Patents)

Location History:

Eppstein, DE (2002 - 2010)
Basel, DE (2010)
Reinach, CH (2010)
Lörrach, DE (2012)
Basel, CH (2005 - 2016)
Lorrach, DE (2016)
Loerrach, DE (2016)

Company Filing History:

15 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

patents

Years Active: 2002-2016

Loading Chart...

Areas of Expertise:

Complement Pathway Modulators

Pyrrolidine Derivatives

Cysteine Protease Inhibitors

Diphenylazetidinones

Kallikrein 7 Modulators

Hexahydropyrazino Derivatives

Dibenzo[b,f]oxepine

Imidazolidine Derivatives

Pyrazoloisoquinoline Derivatives

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9487483 - Complement pathway modulators and uses thereof (2016-11-08),

2. 9464081 - Pyrrolidine derivatives and their use as complement pathway modulators (2016-10-11),

3. 9290485 - N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides (2016-03-22),

4. 8309596 - Kallikrein 7 modulators (2012-11-13),

5. 7772429 - Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use (2010-08-10),

6. 7750005 - Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments (2010-07-06),

7. 7700605 - 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors (2010-04-20),

8. 7674773 - Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use (2010-03-09),

9. 7671047 - Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2010-03-02),

10. 7652007 - Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments (2010-01-26),

11. 7612054 - Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof (2009-11-03),

12. 7579339 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2009-08-25),

13. 7576200 - Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use (2009-08-18),

14. 7488829 - Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use (2009-02-10),

15. 7407938 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use (2008-08-05),

Title: The Innovative Journey of Stefanie Flohr

Introduction: Stefanie Flohr is a pioneering inventor based in Basel, Switzerland, known for her groundbreaking contributions to the field of biotechnology.

Latest Patents: Stefanie Flohr's recent patents focus on novel drug delivery systems that enhance the efficacy of pharmaceutical compounds in treating various diseases.

Career Highlights: With a background in biochemistry and pharmacology, Stefanie Flohr has spent over two decades pushing the boundaries of medical science. Her work has led to the development of innovative therapies for complex medical conditions.

Collaborations: Throughout her career, Stefanie Flohr has collaborated with leading research institutions and pharmaceutical companies to translate her innovative ideas into tangible solutions that benefit patients worldwide.

Conclusion: Stefanie Flohr's relentless pursuit of innovation in biotechnology continues to make a significant impact on the healthcare industry, paving the way for advanced treatment options and improved patient outcomes.

Profile summary based on public USPTO records.